A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events

ConclusionsMultiple doses of TAK-063 were safe and well tolerated. PK/AE models characterized the incidence of somnolence and EPS with increasing TAK-063 exposure, and simulations suggested that a once-daily dose range of up to 30 mg would be suitable for future studies.ClinicalTrials.gov IdentifierNCT01879722.

http://link.springer.com/10.1007/s40268-017-0214-8

Source: Drugs in R&D - November 4, 2017 Category: Drugs & Pharmacology Source Type: research